NCT Number: NCT05765500
Phase:
Trial Summary: This study is testing the way that approved androgen deprivation therapy treatments, Leuprolide and Relugolix, for prostate cancer affect quality of life, blood levels, cholesterol, and blood sugar. T – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Dana-Farber Cancer Institute
Acronym:
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives